Investigational drug · Phase 2
BXQ-350
Also called: SapC-DOPS
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Colorectal Carcinoma, Neuropathy.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "BXQ-350"
First trial start
2023
Jan 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BXQ-350", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Colorectal Carcinoma
- Neuropathy
Approved drugs for the same conditions: Oncology · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "BXQ-350" as an intervention, largest first.
- BXQ-350 in Newly Diagnosed Metastatic Colorectal CarcinomaPivotal-lookingActive, not recruiting
Bexion Pharmaceuticals, Inc.Industry
NCT05322590 · 195 participants (planned) · Start Jan 9, 2023 · Primary completion Nov 2026
Drug: BXQ-350 · For: Metastatic Colorectal Carcinoma; Neuropathy
Sites: Birmingham, Alabama; Orange, California; San Francisco, California · 12 sites in all
Bexion Pharmaceuticals, Inc.Industry
NCT02859857 · 86 participants · Start Sep 1, 2016 · Primary completion Jun 17, 2019
Drug: BXQ-350 · For: Neoplasms
Sites: Lexington, Kentucky; Albuquerque, New Mexico; Cincinnati, Ohio · 4 sites in all
Bexion Pharmaceuticals, Inc.Industry
NCT05291286 · 21 participants · Start Oct 17, 2022 · Primary completion Dec 20, 2024
Drug: BXQ-350 · For: Neuropathy;Peripheral; Chemotherapy-induced Peripheral Neuropathy
Sites: Cincinnati, Ohio; Columbus, Ohio; Nashville, Tennessee
Bexion Pharmaceuticals, Inc.Industry
NCT04771897 · 10 participants · Start May 24, 2021 · Primary completion Oct 4, 2024
Drug: BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance; BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations · For: Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant
Sites: Aurora, Colorado; Cincinnati, Ohio; Columbus, Ohio
Bexion Pharmaceuticals, Inc.Industry
NCT03967093 · 9 participants · Start Apr 15, 2019 · Primary completion Jan 3, 2020
Drug: BXQ-350 · For: Neoplasms
Sites: Cincinnati, Ohio; Columbus, Ohio
Bexion Pharmaceuticals, Inc.Industry
NCT04404569 · 5 participants · Start Jun 8, 2020 · Primary completion Sep 23, 2024
Drug: BXQ-350 · For: Neoplasms
Sites: Lexington, Kentucky; Cincinnati, Ohio; Columbus, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies.
Lin Y, Liou B, Fannin V, et al. · Elife 2026
- Phosphatidylserine Externalization in Cancer: Biology, Immune Suppression, and Emerging Theragnostic Strategies.
Yoo M, Kim KH · Int J Mol Sci 2026
- Patient-Specific Midbrain Organoids with CRISPR Correction Reveal Disease Mechanisms and Enable Therapeutic Evaluation in Neuronopathic Gaucher Disease.
Lin Y, Liou B, Fannin V, et al. · bioRxiv 2025
- A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.
Rixe O, Villano JL, Wesolowski R, et al. · Clin Cancer Res 2024
- An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.
Abdelbaki MS, DeWire Schottmiller MD, Cripe TP, et al. · Heliyon 2022
- Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy.
Kaynak A, Davis HW, Kogan AB, et al. · Cancers (Basel) 2022
Also in development for Metastatic Colorectal Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.